US Patent

US8796245 — C7-fluoro substituted tetracycline compounds

Method of Use · Assigned to Tetraphase Pharmaceuticals Inc · Expires 2029-08-07 · 3y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a compound represented by Structural Formula (A) and its therapeutic use, as well as a pharmaceutical composition comprising the compound.

USPTO Abstract

The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

Drugs covered by this patent

Xerava (ERAVACYCLINE DIHYDROCHLORIDE) · Tetraphase Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2380`	—	Xerava
`U-2380`	—	Xerava

Patent Metadata

Patent number: US8796245
Jurisdiction: US
Classification: Method of Use
Expires: 2029-08-07
Drug substance claim: No
Drug product claim: No
Assignee: Tetraphase Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.